Echinacea and Acute Respiratory Illness
Completed · Not applicable · Has a placebo group
Conditions studied: Acute Respiratory Infections
In brief
The primary objective of this study is to evaluate the effectiveness of ingesting an alkylamide-rich echinacea root product (Quick Defense, Gaia Herbs) for 2 days immediately following each onset of acute respiratory illness (ARI) symptomatology during a 12-week period in the winter and early spring in women. Hypothesis: Subjects randomized to Quick Defense compared to placebo over a 12-week period will experience reduced ARI symptomatology, both acutely during each ARI episode and collectively over the entire 12-week study period.
Key facts
- Study ID
- NCT02003651
- Run by
- Appalachian State University
- People needed
- 40
- Starts
- 2013-11-01
- Expected to finish
- 2014-08-01
- Last updated by the study team
- 2016-12-13
Who can join
Age: 18 and older, up to 55. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Adult women, ages 18 to 55 years.
- Non-smokers.
- Willingness to avoid the use of antibiotics, antivirals, nasal steroids, decongestants, antihistamines, combination cold formulas, echinacea, zinc, or vitamin C during the 12-week study.
- Willingness to maintain normal dietary and physical activity patterns during the 12-week intervention, and not make formal attempts to lose body weight.
You may not qualify if…
- Current history of autoimmune or immune deficiency disease.
- History of moderate to severe allergic rhinitis with sneezing or itching of the nose or eyes during the winter/early spring.
- Current history of asthma with coughing, wheezing, or shortness of breath.
- Pregnant or planning to be pregnant during the study.
- History of gastrointestinal upsets, rashes, or allergic reactions to Echinacea.
Where it is running
- ASU-NCRC Human Performance Lab — Kannapolis, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.